Lexaria has developed and commercialized a patented and cost-effective delivery technology (DehydraTECH™) that has been both laboratory and market proven to enhance the performance of beneficial compounds in ingestible products across four categories:

  • Taste
  • Smell
  • Speed of action
  • Bioabsorption & bioavailability

Lexaria’s technology is easily applied through incorporation of an intermediate step in the formulation and manufacturing of existing or new ingestible products.  This step involves mixing the beneficial compound of interest as a delivery “payload” together with certain fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to conjugate the payload and fatty acids together at a molecular level before integrating the newly-combined molecules into production.

Click on the video above to view a video explaining Lexaria’s DehydraTECH™ technology and illustrating how it is used to formulate and manufacture high performance ingestible consumer products.

A Versatile Solution to Improve Bioabsorption, Taste, and Efficacy

Compounds processed using Lexaria’s DehydraTECH™ system become masked to oral and olfactory receptors, rendering them essentially flavorless and odorless.  As such, DehydraTECH™ formulations do not require unwanted sweeteners or chemical masking agents for flavor and odor blocking.  This allows manufacturers to create low-sugar products with fewer calories, while also avoiding the use of excessive artificial sweeteners.

After being swallowed, the fatty acids are believed to protect the conjugated payload from hostile stomach conditions and expedite its transit to the small intestine where nutrient bioabsorption occurs.  Once in the small intestine, the fatty acids are believed to enable rapid and more significant permeation of the intestinal wall for the conjugated payload, then transport it to the systemic circulation by one of two pathways depending on the type of fatty acid(s) chosen for each specific formulation:

1. Hepatic Transport

In cases where liver metabolism is desirable for biotransformation of the payload before access to the general circulation, Lexaria’s methodology uses medium chain fatty acids for formulation purposes since they are absorbed via the portal vein and transported to the liver for processing prior to entering the general circulation.  This would be applicable, for instance, with prodrug compounds that rely on metabolism by liver enzymes to become pharmacologically active within the human body.

2. Lymphatic Transport

Conversely, in cases where faster onset of action and/or maximizing action of the originally formulated payload without biotransformation is desirable, Lexaria’s methodology uses long chain fatty acids, which are absorbed via the lymphatic lacteals thereby diverting away from the liver and entering the general circulation very quickly.  For payloads that deliver pain relief or meet other immediate needs, this rapidity of onset is a vital benefit.

DehydraTECH™ formulations may also permit formulation with a combination of long and medium chain fatty acids in the same preparation for purposes of engineering products with both fast and sustained release profiles. Such timed-release formulations can be sought to deliver beneficial payloads both quickly, as well as over a sustained duration for several hours.

DehydraTECH™ formulations have been shown through in vitro and in vivo studies to increase intestinal bioabsorption of bioactive compounds by as much as 5-10X and demonstrate effectiveness in as little as 15 minutes after administration (see:  Research).  Lexaria’s DehydraTECH™ process has the added benefit of being very cost-effective to implement; requiring micro quantities of fatty acid ingredient incorporation into food, beverage, and capsule products at a fraction of a penny per serving, together with the use of processing equipment that is readily found in most commercial kitchen/production facilities and is highly scalable.

Commercial Applications

Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) payloads such as cannabis oils.  Over 50 patents-pending or patents granted around the world protect its use with a broad range of bioactive molecules, including cannabis and cannabis-related molecules.

Lexaria’s technology is best thought of as an additional layer that consumer products companies and cannabis companies can utilize to improve the effectiveness of their existing or planned new products, regardless of the type of active ingredient used. Lexaria CanPharm Corp. licenses its advanced technology to other companies around the world to offer consumers the best performance possible in non-combusted cannabis products.

medical cannabinoid research Laxaria Bioscience Technology | Biotechnology Engineering | Cannabinoids

The global legal cannabis industry is growing dramatically. Eight Capital of Toronto estimates a global market of over $100 billion; whereas Grand View Research estimates it at US$146 billion by 2025. It is without doubt one of the fastest growing and most dynamic industries in the world – a rare occurrence of an entire business sector open for innovation at the stroke of a pen. Cannabis enjoys some form of recent legalization – usually medical – in over 30 countries around the world and in over 30 states within the USA.

With legalization comes regulation in a modern world that rejected cigarette smoking a generation ago. In the years to come Lexaria expects that the proportion of customers who smoke cannabis will decline below 25%, as healthier high performance alternatives become more readily available. The human body is designed to obtain its nourishment through ingestion, not through pulmonary absorption.

However, ingestion of cannabinoids like THC is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Long-accepted studies show that that blood absorption of THC through edible products – including capsules – is often as low as about 6%. In other words, without enhancement of some kind, for every 100mg of THC ingested, often as little at 6 mg is actually absorbed into the blood.

Lexaria’s DehydraTECH technology offers a means to formulate ingestible product formats of cannabis and/or its analogues with higher bioavailability performance possibilities due to the benefits of our technology. Lexaria is a pioneer in this field having pushed the industry since 2014 into adopting more bioavailable THC-from-cannabis processes that benefit consumers.

Lexaria’s methodology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets, capsules and more. This is accomplished through choosing an appropriate substrate compound for infusion during performance of the Lexaria formulation and manufacturing process, which can range from a foodstuff like cocoa powder or tapioca starch used in many confectionary products, or an emulsifier like gum arabic used in many beverage products. Many of the most common base ingredients used in modern processing of foods, beverages and supplements are effective to use with DehydraTECH™.


Lexaria’s DehydraTECH

Lexaria’s Patents and Summer/2018 Update


The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness.  Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.

Patent Portfolio

Lexaria’s DehydraTECH™ technology is covered by issued and pending patents in over 40 countries around the world.  Lexaria`s patent suite commenced with two initial 2014 US provisional patent application, which Lexaria acquired by way of exclusive, worldwide license rights and controlling interest in the founding company that made these filings.  Since then, Lexaria has broadened the patent suite considerably by refining the patent claims via further US provisional and utility patent filings and extending the breadth of the claims considerably to name many other beneficial compounds that the technology can be applied to and many other consumer product formats in which they can be formulated.  Under US patent law, a patent upon issuance provides for 20 years of patent protection from the date of filing.


In addition to the US patent filings, Lexaria has also pursued international patent protection through filings under the Patent Cooperation Treaty, followed by national filings in 40+ jurisdictions of highest commercial potential thereunder.